




Supplementary Fig. 3: Pharmacodynamic effect of rogaratinib in T-47D variants. T-47D-LTED-R and FGFR1-overexpressing variants were exposed to pre-incubation with vehicle (Veh) or rogaratinib (R) for 6 hours followed by stimulation with bFGF for 10 minutes (20 ng/ml). It can be appreciated how rogaratinib suppresses phosphorylation of ERK, FGFR1 and FRS2 proteins.